Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 12:35PM GMT
Release Date Price: $73.7
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

We're ready to get started with the next session. I'm Matt Harrison, one of the biotech analysts here. Quickly, before we get started, I just need to read a disclosure statement. Please note that all-important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.

So pleased to have with me Hank Fuchs, who runs R&D; and Dan Spiegelman, who is the CFO of BioMarin. And I think, Dan, you want to make some opening comments, and then we can jump into it.

Daniel K. Spiegelman
BioMarin Pharmaceutical Inc. - Executive VP & CFO

Yes, sure. Just to start by saying that things are going great right now. The core business of BioMarin is on track to generate about $1.7 billion in revenues this year. We're going to have non-GAAP income growth to put us in the $130 million to $170 million this year. A number of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot